Depression and insulin resistance · pain patients

Depression and Insulin Resistance: Screening the Pain Patient

Screen a pain patient with depression for insulin resistance: fasting glucose, A1c, the triglyceride-to-HDL ratio and body composition belong beside the PHQ-9. The two conditions predict each other, and the metabolic pattern predicts how far chronic pain spreads and how procedures perform.

A positive depression screen in a pain patient usually produces a behavioral health referral. The metabolic data that predict how that patient’s mood, pain and procedures will behave rarely travel with it.

Depression and insulin resistance tend to be charted by different clinicians, yet in patients with chronic pain the two predict each other, predict how far the pain spreads, and predict how an injection or an operation performs. A positive PHQ-9 in a pain or primary care clinic generates a referral; the fasting glucose, A1c, lipid ratio and body composition that belong beside it usually do not. The video You Cannot Separate the Mind from the Metabolism covers chapter 21 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Evidence grading sits in the book companion for chapter 21; the concern here is what a primary care, pain, endocrine or geriatric practice should measure once mood and pain arrive together.

How common is depression in chronic pain patients?

In a synthesis of 376 studies and 347,468 people with chronic pain, clinically significant depressive symptoms ran 39.3 percent and diagnosed major depressive disorder 36.7 percent, with fibromyalgia at 54.0 percent. Heterogeneity approached 99 percent and screens were pooled with formal diagnoses, so the diagnosed figure is the conservative one. Pain also impairs the recognition and treatment of depression, so a busy procedural or primary care schedule underdetects it by default.

A depression screen that ends the workup tells the patient her pain is psychological. A screen that extends the workup into the metabolic terrain does the reverse.

Does insulin resistance predict depression, or the reverse?

Cross-sectionally the association is modest, a pooled standardized effect of 0.19 in data excluding prevalent diabetes. Prospectively it is more informative. Baseline depression predicted incident type 2 diabetes at a relative risk of 1.60, and baseline diabetes predicted incident depression at 1.15. In the NESDA cohort, 601 adults without lifetime depression or anxiety were followed nine years: a higher triglyceride-to-HDL ratio predicted first-onset major depression at a hazard ratio of 1.89, fasting glucose at 1.37, waist circumference at 1.11, and prediabetes developing within two years at 2.66. These are surrogate measures rather than clamp studies, and new-onset lipid ratio elevation was not associated, but the metabolic signal preceded the mood disorder.

The inflammatory subgroup is real and bounded. Across 37 studies, CRP exceeded 3 mg/L in 27 percent of depressed patients and 1 mg/L in 58 percent, at odds of 1.46 and 1.47 against matched controls, without variation by antidepressant treatment, age or BMI. Roughly three quarters fall below the higher threshold. CRP stratifies; it does not diagnose.

Pharmacotherapy sits inside the same loop. In 294,719 adults in the UK Clinical Practice Research Datalink, antidepressant use carried an adjusted rate ratio of 1.21 for at least 5 percent weight gain, persisting at least six years, with one additional weight-gain episode per 27 patients treated in year two. Neither finding argues against prescribing. Both argue for a documented baseline weight, body composition and fasting glucose before the first dose.

How does metabolic status change pain and procedure outcomes?

In MIDUS, 24.2 percent of 781 adults showed a metabolic dysregulation phenotype defined by fasting glucose, HbA1c, HOMA-IR, triglycerides, waist-hip ratio and low HDL. About seven years later that phenotype carried a relative risk ratio of 2.00 for high-interference chronic pain and 2.03 for pain at three or more sites, while it did not predict the presence of chronic pain, an odds ratio of 1.18. The metabolic terrain forecasts spread and interference, which are the outcomes pain practices are asked to change.

It also forecasts procedural yield. Across 346 patients in seven hospitals receiving epidural steroid injections, sacroiliac injections or facet radiofrequency ablation, depressive symptoms lowered the odds of success by an adjusted 0.94 per unit of score, obesity reduced relief, and poor baseline function cut the odds to 0.59. With metabolic syndrome, spine surgery carried 1.6 times the wound complications and 4.48 times the renal complications. Across 44 studies and 21,452 spine surgery patients, depressed patients started 0.52 standardized units worse and finished 0.52 worse, with identical improvement: the operation worked and the depression stayed.

A documented mood and metabolic phenotype sets expectations before a procedure. It justifies treating layers together; in SCAMP, 250 primary care patients with musculoskeletal pain and a PHQ-9 of at least 10 who received optimized antidepressant therapy plus pain self-management reached combined improvement in depression and pain at 26.0 percent against 7.9 percent, a relative risk of 3.3. And it names the social driver neither specialty owns: in older Chinese adults without chronic pain at baseline, loneliness carried an odds ratio of 1.61 for incident chronic pain over seven years.

Which pain patients should be screened for insulin resistance?

• Chronic pain patients with a positive PHQ-9 or a documented depressive disorder.
• Pain that is spreading to new sites or increasingly interfering with function.
• Patients about to start or escalate an antidepressant associated with weight gain.
• Candidates for epidural, sacroiliac, radiofrequency or spinal surgical procedures who have depressive symptoms, obesity or poor baseline function.
• Patients with prediabetic glycemia or an elevated triglyceride-to-HDL ratio who have never been screened for mood.

Selection thresholds for a practice are listed in selection criteria.

What Measura measures in this pathway

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service: it measures, returns results to the ordering physician, and does not diagnose depression or treat. Laboratory panels are the route for the glycemic, lipid and inflammatory markers used in the cohorts above. Bioimpedance body composition separates fat from lean mass, which matters when an antidepressant or a sedentary year shifts weight and when BMI understates risk. Heart rate variability adds an autonomic dimension; baseline autonomic measures did not predict improvement in 665 NESDA participants with multisite pain, so it serves as a trended descriptor, not a prognostic score. In older patients whose complaints include memory or processing change, the cognitive assessment and fall prevention workflow documents a separate domain; a cognitive test is not a depression instrument and should not be read as one.

Standing orders and documentation

The reproducible version is a standing order that attaches fasting glucose, A1c, a lipid panel with the triglyceride-to-HDL ratio, C-reactive protein and body composition to any positive depression screen in a chronic pain patient, and to any pre-procedure evaluation in a patient with depressive symptoms. The baseline then exists before the antidepressant, the injection or the referral, and a scheduled repeat shows whether a combined plan is moving the terrain. The same results support the documentation that MIPS and quality reporting frameworks already track, and filing them as structured data through getting results into the record keeps them visible to the behavioral clinician and the interventionalist at once. The broader argument is in why metabolic health belongs in a pain practice.

The limits, stated once

The evidence is largely observational, the markers are surrogates, and the inflammatory signal describes a subgroup. The practice position stands: mood and metabolism are one system, and small effects that stack are the honest offer. Measure both layers at baseline, treat them together, and remeasure. What happens when that plan leaves the clinic is the subject of referral to diabetes prevention with measurement; patients can read the patient version.

Frequently asked questions

How is insulin resistance checked in a pain patient?

With routine measurements rather than a single test. The cohorts cited here used fasting glucose, HbA1c, HOMA-IR, triglycerides with HDL as a ratio, and waist or waist-hip ratio; prediabetic glycemia and an elevated triglyceride-to-HDL ratio are the practical flags. Body composition adds whether weight is fat or lean mass. Recorded at baseline and repeated on a schedule, these values show whether a combined plan is moving the terrain.

Is insulin resistance associated with depression?

Yes, in both directions and prospectively. Depression predicted incident type 2 diabetes at a relative risk of 1.60, and in a Dutch cohort without prior depression, a higher triglyceride-to-HDL ratio predicted first-onset major depression at a hazard ratio of 1.89 and incident prediabetes at 2.66. The cross-sectional association is small and the markers are surrogates. The clinical rationale for cardiometabolic measurement follows the same logic.

Which laboratory values belong beside a positive depression screen in a pain patient?

The markers studied are fasting glucose, HbA1c, triglycerides and HDL as a ratio, waist or body composition, and C-reactive protein, which identifies the inflammatory subgroup at thresholds of 3 and 1 mg/L. None of them diagnoses depression; together they describe the terrain the mood disorder and the pain share. Available panels are described under laboratory panels.

Should mood and metabolic status be documented before an interventional procedure?

The prospective data support it. Depression score and poor baseline function predicted injection and ablation failure across seven hospitals, obesity reduced relief, and metabolic syndrome raised wound and renal complications after spine surgery. Documentation is not a reason to withhold a procedure that serves as a bridge; it sets expectations and adds the work that fills the window. Reading the results is covered in interpreting the report.

How should weight change on an antidepressant be monitored?

With a baseline and a scheduled recheck. In a UK cohort of 294,719 adults, antidepressant use carried a rate ratio of 1.21 for gaining at least 5 percent of body weight, persisting six years or more. Body composition distinguishes fat gain from other change, and fasting glucose tracks the metabolic consequence. Between-visit tracking is outlined in chronic care and between-visit monitoring.

Where does this fit in an annual wellness visit?

The annual wellness visit is a structured point for reviewing risk factors, which makes it a practical place to pair a positive mood screen with metabolic measurement in patients who also report chronic pain. Results serve as documentation and trend data rather than an indication by themselves, and they give the next visit a comparison point. Workflow options are in annual wellness visit integration.

References

• Aaron, R. V., Ravyts, S. G., Carnahan, N. D., Bhattiprolu, K., Harte, N., McCaulley, C. C., Vitalicia, L., Rogers, A. B., Wegener, S. T., & Dudeney, J. (2025). Prevalence of Depression and Anxiety Among Adults With Chronic Pain: A Systematic Review and Meta-Analysis. JAMA Network Open, 8(3), e250268. https://doi.org/10.1001/jamanetworkopen.2025.0268
• Kan, C., Silva, N., Golden, S. H., Rajala, U., Timonen, M., Stahl, D., & Ismail, K. (2013). A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care, 36(2), 480–9. https://doi.org/10.2337/dc12-1442
• Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008). Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care, 31(12), 2383–90. https://doi.org/10.2337/dc08-0985
• Watson, K. T., Simard, J. F., Henderson, V. W., Nutkiewicz, L., Lamers, F., Nasca, C., Rasgon, N., & Penninx, B. W. J. H. (2021). Incident Major Depressive Disorder Predicted by Three Measures of Insulin Resistance: A Dutch Cohort Study. Am J Psychiatry, 178(10), 914–920. https://doi.org/10.1176/appi.ajp.2021.20101479
• Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019). Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med, 49(12), 1958–1970. https://doi.org/10.1017/S0033291719001454
• Gafoor, R., Booth, H. P., & Gulliford, M. C. (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ, 361, k1951. https://doi.org/10.1136/bmj.k1951
• Liang, Y., & Booker, C. (2024). Allostatic load and chronic pain: a prospective finding from the national survey of midlife development in the United States, 2004-2014. BMC Public Health, 24(1), 416. https://doi.org/10.1186/s12889-024-17888-1
• Cohen, S. P., Doshi, T. L., Kurihara, C., Reece, D., Dolomisiewicz, E., Phillips, C. R., Dawson, T., Jamison, D., Young, R., & Pasquina, P. F. (2021). Multicenter study evaluating factors associated with treatment outcome for low back pain injections. Regional Anesthesia and Pain Medicine, 47(2), 89–99. https://doi.org/10.1136/rapm-2021-103247
• Javeed, S., Benedict, B., Yakdan, S., Saleem, S., Zhang, J. K., Botterbush, K., Frumkin, M. R., Hardi, A., Neuman, B., Kelly, M. P., Steinmetz, M. P., Piccirillo, J. F., Goodin, B. R., Rodebaugh, T. L., Ray, W. Z., & Greenberg, J. K. (2024). Implications of Preoperative Depression for Lumbar Spine Surgery Outcomes: A Systematic Review and Meta-Analysis. JAMA Network Open, 7(1), e2348565. https://doi.org/10.1001/jamanetworkopen.2023.48565
• Kroenke, K., Bair, M. J., Damush, T. M., Wu, J., Hoke, S., Sutherland, J., & Tu, W. (2009). Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA, 301(20), 2099–110. https://doi.org/10.1001/jama.2009.723

Related reading

• The Sudomotor Test in Mixed Pain: What It Adds and What It Cannot
• The Diabetes Prevention Program in Pain and Primary Care
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.